Goldman Sachs
IMNM icon

Goldman Sachs’s Immunome IMNM Stock Holding History

Goldman Sachs’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32M Buy
1,512,489
+411,013
+37% +$8.79M ﹤0.01% 2194
2026
Q1 		$24.1M Buy
1,101,476
+348,751
+46% +$7.76M ﹤0.01% 2262
2025
Q4 		$16.2M Buy
752,725
+543,779
+260% +$9.54M ﹤0.01% 2586
2025
Q3 		$2.45M Sell
208,946
-269,672
-56% -$2.68M ﹤0.01% 4300
2025
Q2 		$4.45M Buy
478,618
+285,316
+148% +$2.34M ﹤0.01% 3536
2025
Q1 		$1.3M Sell
193,302
-80,459
-29% -$772K ﹤0.01% 4494
2024
Q4 		$2.91M Sell
273,761
-294,747
-52% -$3.56M ﹤0.01% 3978
2024
Q3 		$8.31M Buy
568,508
+384,260
+209% +$5.46M ﹤0.01% 2904
2024
Q2 		$2.23M Sell
184,248
-147,516
-44% -$2.31M ﹤0.01% 3836
2024
Q1 		$8.19M Buy
+331,764
New +$6.73M ﹤0.01% 2658

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Goldman Sachs's IMNM Position: Q2 2026 in Review

Goldman Sachs increased its Immunome (IMNM) stake by 37% in Q2 2026, buying an estimated $8.79M and bringing the position to 1,512,489 shares worth $32M. The position accounts for ﹤0.01% of the portfolio, ranked #2194.

Goldman Sachs first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Goldman Sachs held 1,512,489 shares of Immunome worth $32M as of Q2 2026.
  • Goldman Sachs bought 411,013 Immunome shares in Q2 2026, an estimated $8.79M.
  • Immunome made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2194 holding.
  • Goldman Sachs first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.